

Helena Florindo obtained her Ph.D. degree in Pharmaceutical Technology in 2008 (University of Lisbon), in collaboration with the University of London. She is an Associate Professor with tenure and habilitation in the department of Pharmacy, Pharmacology and Health Technologies at the Faculty of Pharmacy, University of Lisbon. Since 2015, she is the head of the BioNanoSciences – Drug Delivery & Immunoengineering Research Group, at the Research Institute for Medicines (iMed.Ulisboa), University of Lisbon. Since 2022, she is the President of the Spanish-Portuguese Local Chapter at the Controlled Release Society.

Both nanotechnology and immune-oncology fields have motivated her multidisciplinary research focused on:

- 1) Regulation of immunity by targeting dendritic cells (DC) to i) enhance antigen delivery and modulate antigen presentation pathways; iii) block signalling pathways related to tumour evasion mechanisms.
- 2) Size-based targeting of lymph node-resident immune cells by NP to overcome major barriers for vaccine components and immunotherapies.
- 3) Dissecting tumor stromal and immune cell interplay to guide the design of multi-targeting nano-conjugates as innovative immunotherapeutic treatments against metastatic cancer diseases.